G Cole - Genomic Health COO
COO
Mr. G. Bradley Cole is Chief Financial Officer Chief Operating Officer Principal Financial Officer Principal Accounting Officer of Genomic Health Inc. he served in various roles at Guidant Corporation a medical device company most recently serving as Vice President Finance and Business Development for the Endovascular Solutions Group from January 2001 until May 2004. From July 1994 to December 1997 Mr. Cole was Vice President Finance and Chief Financial Officer of Endovascular Technologies Inc. a medical device company that was acquired by Guidant Corporationrationration. From December 1988 to February 1994 he served as Vice President Finance and Chief Financial Officer of Applied Biosystems Incorporated a life sciences systems company since 2014.
| Age | 58 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 650 556-9300 |
| Web | www.genomichealth.com |
Genomic Health Management Efficiency
The company has return on total asset (ROA) of 0.11 % which means that it generated a profit of $0.11 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.14 %, meaning that it created $0.14 on every $100 dollars invested by stockholders. Genomic Health's management efficiency ratios could be used to measure how well Genomic Health manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 55.62 M in liabilities with Debt to Equity (D/E) ratio of 15.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Genomic Health has a current ratio of 5.84, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Genomic Health until it has trouble settling it off, either with new capital or with free cash flow. So, Genomic Health's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genomic Health sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genomic to invest in growth at high rates of return. When we think about Genomic Health's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 3 records | COO Age | ||
| Dieter Wunderlich | Vishay Intertechnology | 62 | |
| Jeffrey Webster | Vishay Intertechnology | 53 | |
| Michael Plunkett | Alphatec Holdings | 59 | |
Management Performance
| Return On Equity | 0.14 | |||
| Return On Asset | 0.11 |
Genomic Health Leadership Team
Elected by the shareholders, the Genomic Health's board of directors comprises two types of representatives: Genomic Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genomic. The board's role is to monitor Genomic Health's management team and ensure that shareholders' interests are well served. Genomic Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genomic Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henry Fuchs, Director | ||
| Fred Cohen, Independent Director | ||
| Laura Kammeyer, Chief Communications Officer | ||
| Felix Baker, Independent Director | ||
| Randy Livingston, Independent Director | ||
| Kim McEachron, Chief People Officer | ||
| Steven Shak, Executive Vice President - Research and Development | ||
| Geoffrey Parker, Director | ||
| Randall Livingston, Independent Director | ||
| Gordon Cole, CFO, COO, Secretary | ||
| Jason Radford, Chief Legal Officer and Secretary | ||
| Barry Flannelly, Director | ||
| G Cole, CFO, COO, Principal Financial Officer, Principal Accounting Officer | ||
| Phillip Febbo, Chief Medical Officer | ||
| Ginger Graham, Independent Director | ||
| Julian Baker, Managing Partner, Lead Independent Director and Chairman of Nominating and Corporate Governance Committee | ||
| Frederic Pla, Chief Business and Product Development Officer | ||
| James Vaughn, Chief Commercial Officer | ||
| Kimberly Popovits, Chairman, CEO and President and Member of Non-Management Stock Option Committee |
Genomic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genomic Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 15.37 % | |||
| Current Valuation | 2.31 B | |||
| Shares Outstanding | 37.59 M | |||
| Shares Owned By Insiders | 2.77 % | |||
| Shares Owned By Institutions | 86.93 % | |||
| Number Of Shares Shorted | 1.34 M | |||
| Price To Earning | 43.57 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Genomic Health in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Genomic Health's short interest history, or implied volatility extrapolated from Genomic Health options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Genomic Health information on this page should be used as a complementary analysis to other Genomic Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Genomic Stock
If you are still planning to invest in Genomic Health check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genomic Health's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |